In mice with cisplatin-induced acute kidney injury (AKI), a single dose of ketamine reduced kidney damage, pathological changes in other organs, and depression-like behaviors. The beneficial effects were reversed by blocking the TrkB receptor, and analysis implicated the TrkB and ERK-CREB signaling pathways and blood metabolites like C16-ceramide. The findings suggest ketamine may alleviate both kidney injury and associated depressive symptoms, though the role of the kidney-brain axis remains unclear.
Low-dose esketamine may reduce the incidence of intraoperative hypoxaemia during non-intubation thoracoscopic surgery. This randomized controlled trial will assign patients to receive either esketamine or a placebo (normal saline). The main outcomes are the occurrence of hypoxaemia (oxygen saturation ≤90% for at least 10 seconds) and the time until it appears. Secondary outcomes include hypercapnia, inflammatory markers, pain scores, recovery times, and complications. The trial is registered and approved by an ethics committee.